Liquid Biopsy and Pancreas Cancer: Detection of AXL(+) CTCs (CTC-AXL-PANC)

In solid cancers, some more aggressive tumor cells actively detach from the primary lesion and then travel through the circulating compartment to reach distant organs and form micro-metastases. These circulating tumor cells (CTCs) that have become disseminated tumor cells (DTCs) flourish in their new environments and may remain dormant for many years after the complete resection of the primary tumor. Detecting CTCs in the blood is also relevant for assessing tumor progression, prognosis and therapeutic follow-up. The non-invasive, highly sensitive for CTCs analysis is called "liquid biopsy". P

Trial Details

NCT ID
NCT05346536
Phase
NA
Sponsor
University Hospital, Montpellier
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • Detection of circulating tumor cells expressing Axl: CTC-AXL(+)
Locations (sample)
  • Montpellier, France|43.61093,3.87635

Key Eligibility Criteria

  • The patient is at least 18 years old;
  • Patients with pancreatic cancer with remote metastases, naïve of any treatment, that is, eligible for a first line of treatment;
  • Patients with oral consent

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →